S.E.T. Product sales increased 56 percent worldwide and improved 52 percent in the U.S. Excluding the Trauma Acquisition, S.E.T. Product sales increased 8 percent and increased 11 percent in the U.S. Initiated refinancing actions to lessen cost of overall personal debt capital structure First Quarter Financial Results Net sales increased 6 percent through the first one fourth of fiscal year 2013 to $707.4 million in comparison to net product sales of $664.6 million through the first quarter of fiscal season 2012.Human therapeutic products need a high amount of purity to meet up the hurdles of regulatory authorization. These varied cell lines possess applications in simple laboratory research and so are getting marketed for that purpose. Furthermore, most of the ACTCellerate cell lines may possess essential human therapeutic applications. A few of these therapeutic applications will demand the reconstitution of cells with ECM to produce the architecture of a cells, a field referred to as tissue engineering.